Pharmacokinetic study of the low-molecular-weight heparin fraxiparin in patients with nephrotic syndrome.
We studied the pharmacokinetics of the low-molecular-weight heparin (LMWH) Fraxiparin in 6 patients with the nephrotic syndrome. Maximal plasma anti-Xa activity was obtained 5 h after a subcutaneous injection of 60 IU anti-Xa/kg. Anti-Xa activity was no longer detectable 24 h postinjection. These results are similar to those obtained with the same dosage in other clinical settings. The biological response to a daily subcutaneous injection of 60 IU anti-Xa/kg was studied for 8 days. No cumulative effect was observed. All the patients had an abnormal activation state of hemostasis mechanisms before treatment, as shown by high prothrombin fragment 1 + 2 and D-dimer levels, which were not decreased by Fraxiparin. It remains to be determined whether a higher dosage of LMWH might attenuate the hypercoagulability in these patients.
Alhenc-Gelas
M
M
Laboratoire d'Hémostase, Hôpital Broussais, Paris, France.
Rossert
J
J
Jacquot
C
C
Aiach
M
M
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000493:pharmacokinetics*; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D006495:Heparin, Low-Molecular-Weight / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017762:Nadroparin / Q000493:pharmacokinetics*; D009404:Nephrotic Syndrome / Q000097:blood / Q000188:drug therapy*; D013997:Time Factors
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D017762:Nadroparin